WO2017167209A1 - Cellules souches mésenchymateuses sécrétant la protéine trail et leur utilisation pour traiter les tumeurs cérébrales - Google Patents

Cellules souches mésenchymateuses sécrétant la protéine trail et leur utilisation pour traiter les tumeurs cérébrales Download PDF

Info

Publication number
WO2017167209A1
WO2017167209A1 PCT/CN2017/078684 CN2017078684W WO2017167209A1 WO 2017167209 A1 WO2017167209 A1 WO 2017167209A1 CN 2017078684 W CN2017078684 W CN 2017078684W WO 2017167209 A1 WO2017167209 A1 WO 2017167209A1
Authority
WO
WIPO (PCT)
Prior art keywords
construct
trail
vector
trail protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/078684
Other languages
English (en)
Chinese (zh)
Inventor
胡祥
潘伟生
路钢
徐明恺
刘沐芸
苏献伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Beike Biotechnology Co Ltd
Original Assignee
Shenzhen Beike Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201710184390.6A external-priority patent/CN107287224A/zh
Application filed by Shenzhen Beike Biotechnology Co Ltd filed Critical Shenzhen Beike Biotechnology Co Ltd
Priority to US16/089,992 priority Critical patent/US20200318137A1/en
Publication of WO2017167209A1 publication Critical patent/WO2017167209A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Definitions

  • the present invention relates to the field of genetic recombination and stem cell applications.
  • the present invention provides a construct which expresses a soluble fragment of a secreted TRAIL protein, and a lentiviral expression vector comprising the construct, and a stem cell in which the construct is integrated on the genome, which is expressible And secreting the TRAIL protein fragment.
  • the invention also provides the use of the construct or vector or stem cell for treating a brain tumor or preparing a brain tumor drug.
  • TRAIL Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
  • DR4 and DR5 cell death receptors
  • the apoptosis-inducing activity is mainly directed against tumor cells, and does not have a killing effect on normal cells, and thus has certain tumor specificity.
  • the most economical way to get TRAIL protein It is a genetically engineered expression purification system, and the currently used expression system includes an E. coli prokaryotic expression system and a cellular eukaryotic expression system. Since TRAIL proteins are of mammalian origin, eukaryotic cell expression systems have better compatibility.
  • TRAIL protein solubility The amino terminus of TRAIL protein molecule is a hydrophobic membrane transmembrane structure, which concentrates a large number of hydrophobic amino acid residues, resulting in poor water solubility of TRAIL protein, which tends to accumulate in solution and lose activity. 3.
  • the genetic stability of the constructed genetically engineered cells, the common eukaryotic expression vector, can not be stably existed after the target gene fragment is introduced into the host cell genome, and the target gene will be gradually lost as the host cell undergoes the division process, so it is necessary Constant antibiotic selection and monoclonal cell screening.
  • constructs, vectors and host cells that are capable of stably and efficiently expressing and secreting active TRAIL proteins or fragments.
  • constructs, vectors and host cells that are capable of treating diseases and for the preparation of related drugs that are capable of stably and efficiently expressing and secreting active TRAIL proteins or fragments.
  • the present invention has been made in view of the above problems, and provides a mesenchymal stem cell in which an exogenous nucleic acid is integrated on its genome, which stably and efficiently expresses and secretes a TRAIL protein fragment.
  • the present invention also constructs a lentiviral expression vector capable of expressing a soluble fragment of a secreted TRAIL protein, which stably transfects a mammalian host cell and secretes the soluble fragment of the expressed TRAIL protein into the host cell.
  • the cell culture medium facilitates subsequent collection, isolation and purification.
  • the present invention also provides the use of the mesenchymal stem cells for treating a TRAIL-related disease or preparing a drug, including cancer or tumor, Especially brain tumors.
  • the invention provides an isolated construct, wherein the construct comprises (1) a secretion signal peptide coding region; (2) a TRAIL protein trimer stable structural coding region; and (3) a TRAIL protein fragment Coding area,
  • TRAIL protein fragment has an amino acid sequence identical or substantially identical to the amino acid sequence of (a) or (b) below:
  • the secretory signal peptide of eukaryotes is present on the protein to be secreted or will become a transmembrane part, usually at the N-terminus of the protein.
  • the signal peptide referred to in the present invention may be a heterologous signal peptide, i.e., a signal peptide that is not naturally operably linked to a protein or polypeptide.
  • a signal peptide allows the target protein or polypeptide to be secreted to the extracellular or increased secretion of the protein.
  • Common signal peptides include fibrillin secretion signal peptide, growth factor signal peptide, hormone signal peptide, cytokine signal peptide and immune protein signal peptide.
  • signal peptides examples include GDF signal peptides, IGF signal peptides, BMP signal peptides, neurotrophin signal peptides, PDGF signal peptides and EGF signal peptides, and hormone signal peptides (eg, production hormone, insulin, ADH, LH, FSH, ACTH, MSH). , TSH), or an interleukin signal peptide.
  • hormone signal peptides eg, production hormone, insulin, ADH, LH, FSH, ACTH, MSH).
  • TSH interleukin signal peptide.
  • Most of these signal peptides are derived from mammalian sources, such as humans, mice, rats, pigs, monkeys, etc.
  • the signal peptides used in the present invention are of mouse or human origin.
  • the signal peptide can also be modified to enhance its ability to aid protein secretion.
  • the secretion signal peptide used in the construct of the present invention may be selected from the group consisting of a human fibrillin secretion signal peptide, a human growth hormone secretion signal peptide, a human immunoglobulin signal peptide, and a human interleukin 2 signal peptide. Wait.
  • the secretion signal peptide preferably used in the present invention is a secretion signal peptide derived from human fibrillin.
  • Human fibrillin-1, or human fibrillin by Sakai LY, Keene DR, Engvall E et al., 1986, J. Cell Biol. 103, "Fibrillin, a new 350-kD glycoprotein, is a component Of extracellular microfibrils" was reported.
  • Human fibrillin is a secretable glycoprotein secreted by fibroblasts into the extracellular matrix.
  • the human fibrillin secretion signal peptide has the following amino acid sequence: MRRGRLLEIALGFTVLLASYTSHGADA. Nucleic acid sequences encoding human fibrin secretion signal peptides can be used in the constructs of the invention.
  • the secretion signal peptide coding region has the sequence shown in SEQ ID NO: 2.
  • the TRAIL protein trimer stabilizing structure is used to help form a stable TRAIL protein or a trimer form of a TRAIL fragment.
  • the trimer form of the TRAIL protein or TRAIL fragment is more stable and more active than the monomer.
  • Trimeric stable structural sequences useful in the present invention include isoleucine zipper structures, leucine zipper structures, and the like.
  • the Leucine zippers structure refers to the presence of a leucine residue every 7 amino acid residues in a peptide chain of a trans-factor, and the helix formed by this peptide chain is composed of a bright ammonia.
  • the hydrophobic surface formed by the acid residue and the other side is the hydrophilic surface composed of the hydrophilic amino acid residue.
  • the hydrophobic surface composed of leucine residues is a leucine zipper strip, and two trans-factors having a leucine zipper strip can form a dimer or a multimer such as a trimer by hydrophobic interaction.
  • the leucine zipper domain or the isoleucine zipper structure can interact to form a dimer or trimer.
  • the leucine zipper domain or the isoleucine zipper structure contained in the construct of the present invention can promote oligomerization of the fusion protein and thus can increase stability.
  • Suitable human leucine zipper domains are, for example, the leucine zipper domains contained in the human c-fos, c-jun, c-myc, max and mdx1 proteins.
  • Optimizations and experiments have been performed to demonstrate that the expressed TRAIL protein fragment forms a trimer leucine zipper or isoleucine zipper structural sequence.
  • the inventors obtained an optimized nucleic acid sequence encoding an isoleucine zipper structure sequence by design and testing.
  • the TRAIL protein trimer stable structural coding region has the sequence shown in SEQ ID NO: 3.
  • the TRAIL protein fragment is a fragment of amino acid sequence 114-281 amino acids of SEQ ID NO: 1.
  • Human TRAIL is known in the art to be a type II transmembrane protein consisting of 281 amino acids. Wiley, S. R. et al., is reported in Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis. Immunity 3, 673-682 (1995). The amino acid sequence of the TRAIL protein is shown in SEQ ID NO: 5.
  • the protein encoded by the TRAIL coding region comprised by the construct of the present invention may be a fragment of the active TRAIL, i.e., a contiguous portion of the 281 amino acid amino acid sequence of TRAIL, which has activity of the TRAIL protein.
  • Preferred TRAIL fragments of the invention include, for example, a fragment of 114-281 amino acid residues of TRAIL of SEQ ID NO: 1. It is known in the art that the intracellular N-terminus of TRAIL has no signal peptide and the active portion is located extracellularly from 114 to 281 amino acid residues.
  • the 114-281 amino acid residues of human TRAIL can also form homotrimers with zinc binding sites near the top, which play an important role in maintaining TRAIL and stability.
  • the protein encoded by the TRAIL coding region comprised by the construct of the present invention may also have an amino acid sequence substantially identical to the 114-281 fragment of TRAIL.
  • substantially identical amino acid sequence refers to the substitution, deletion, addition or insertion of one to several (eg, 2, 3, 4 or 5) amino acids in an amino acid sequence which is identical to the amino acid sequence. Or similar or better activity.
  • the constructs of the invention can be prepared by using conventional DNA synthesis.
  • the construct can be inserted into an expression vector by conventional genetic engineering methods; the host cell can be transformed with the obtained recombinant expression vector; Transformants; and collecting the polypeptide from the culture. This can be done, for example, by the method described in Molecular Cloning, T. Maniatis et al., CSH Laboratory (1983).
  • the invention also provides a vector comprising the construct described above.
  • the vector of the present invention may be a plasmid, a bacteriophage, a virus, or the like, and is capable of independently replicating and having a selection marker in a genetically engineered host capable of expressing a protein.
  • the vector is amplified and expressed upon entry into the host cell. Suitable genetically engineered hosts are well known in the art and can be E. coli, yeast, insect cells, animal cells, and the like.
  • the vector of the present invention is a vector expressed in an animal cell, such as a non-viral vector, a baculovirus expression vector, an adenovirus vector, a retroviral vector, a lentiviral vector.
  • the vector which can be used as the present invention is preferably a lentiviral vector such as a lentiviral vector pCDH, specifically pCDH having the aforementioned construct of the present invention.
  • the present invention provides pCDH-seTRAIL prepared as in the examples.
  • the present invention also provides a cell, particularly a mammalian cell, such as a human, mouse, rat, porcine, or monkey cell, genomically integrating the above-described construct of the present invention, and expressing and secreting the TRAIL Protein fragment.
  • a mammalian cell such as a human, mouse, rat, porcine, or monkey cell
  • the mammalian cells of the present invention described above may be stem cells, lymphocytes, T cells, B cells, macrophages, fibroblasts, tumor cells, and the like.
  • the present invention provides a stem cell, such as a mesenchymal stem cell, which integrates the aforementioned construct of the present invention on its genome and which expresses and secretes a TRAIL protein fragment.
  • Mesenchymal stem cells are important members of the adult stem cell family and are derived from the mesoderm and ectoderm in early development. Mesenchymal stem cells have the characteristics of multi-directional differentiation, hematopoietic support and promotion of stem cell implantation, immune regulation and self-replication. The study found that mesenchymal stem cells can differentiate into various tissue cells such as fat, bone, cartilage, muscle, tendon, ligament, nerve, liver, heart muscle, endothelium, etc. under continuous induction conditions in vivo or in vitro, and successively subculture and freeze. Still after saving Have a multi-directional differentiation potential. According to the source, mesenchymal stem cells can be classified into umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, and adipose-derived mesenchymal stem cells.
  • the present invention provides the above-described construct in which the construct of the present invention is integrated on a genome, and mammalian cells which can express and secrete the TRAIL protein fragment are prepared by the following method:
  • constructs of the invention comprising (1) a secretion signal peptide coding region; (2) a TRAIL protein trimer stable structural coding region; and (3) a TRAIL protein fragment coding region ,
  • TRAIL protein fragment has an amino acid sequence identical or substantially identical to the amino acid sequence of (a) or (b) below:
  • the vector is an animal cell expression vector, preferably a lentiviral vector, such as pCDH;
  • a stem cell such as a mesenchymal stem cell.
  • the invention also provides a method for producing a TRAIL protein, the method comprising transforming a mammalian cell with the vector described above, expressing a TRAIL protein in the mammalian cell, the TRAIL protein being secreted into a culture outside the host cell In the liquid.
  • the present invention provides a pharmaceutical composition for treating a disease associated with TRAIL, which comprises any of the above-described constructs or vectors or cells of the present invention.
  • the present invention provides the use of any of the above constructs or vectors or cells of the present invention or a pharmaceutical composition thereof for the treatment of a disease associated with TRAIL.
  • the present invention also provides any of the above uses of the present invention.
  • any of the constructs or vectors or cells of the invention or a pharmaceutical composition thereof can be used to treat a disease with a DR4 or DR5 receptor on a target cell.
  • Diseases treatable by the present invention include cancers and tumors such as brain cancer.
  • the brain tumors treatable by the present invention include glioma and meningioma and the like.
  • Glioma includes glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, and degenerative ganglion nerves.
  • Glioma anaplastic ganglioglioma
  • pineal cell tumor pineoblasoma
  • medullobastoma medullobastoma
  • Fig. 1 is an agarose gel electrophoresis pattern of a secreted TRAIL protein soluble fragment-expressed gene recovered by double digestion. On the right is the DNA band of interest, and on the left is Invitrogen's 1Kb Plus DNA ladder molecular marker. The target nucleic acid fragment is approximately 711 bp.
  • Figure 2 is an electrophoresis map of the lentiviral expression vector pCDH plasmid DNA recovered by double digestion.
  • the left side is the DNA band of interest, and the right side is the Invitrogen 1Kb Plus DNA ladder molecular marker used.
  • the target nucleic acid fragment is approximately 8,000 bp.
  • Figure 3 is a fluorescence micrograph of HEK293 cells co-transfected with lentivirus-packaged four plasmids for 48 hours.
  • GFP is a photo under fluorescence
  • Light is a white light photo in the same field of view
  • Merge is an integrated photo of two fields of view.
  • FIG. 4 Fluorescence and white light micrographs of MSC cells infected with lentiviral particles.
  • GFP is a photo under fluorescence
  • Light is a white light photo in the same field of view
  • Merge is an integrated photo of two fields of view.
  • Figure 5 shows an ELISA standard curve for detecting TRAIL protein.
  • the abscissa is the absorbance at 450 nm and the ordinate is the TRAIL protein standard concentration (pg/ml).
  • Fig. 6 MTS assay detects the growth inhibitory effect of conditioned medium of MSC cells infected with lentivirus on U87 tumor cells.
  • Figure 7 Stability of TRAIL protein secreted by MSC cells infected with lentiviral vectors.
  • a double-stranded DNA molecule having the nucleotide sequence of SEQ ID NO: 4 below was synthesized.
  • Trimeric stable structure coding region sequence
  • the synthesized double-stranded DNA molecules were fully digested with restriction endonucleases Xba I and BamH I (NEB), and the digested products were analyzed by 1% agarose gel electrophoresis.
  • the 711 bp nucleic acid fragment was purified by Qiagen's gel recovery kit. (figure 1).
  • Double digestion of pCDH vector The pCDH vector plasmid (System Biosciences Catalog: CD513B-1) was fully digested with restriction endonucleases Xba I and BamH I (NEB). The product was analyzed by 0.8% agarose gel electrophoresis, and an approximately 8000 bp fragment was purified using Qiagen's gel recovery kit (Fig. 2).
  • the ligation product was transformed into E. coli stbls competent cells (stbls competent cells were purchased from Genecopoeia, transformed operations by F. Osbourne, R. Brent, RE guitarist, DD Moore, JG Seidman, JA Smith K. Straer, "Guidelines for Editing Molecular Biology", John Wiley & Sons, New York, 1995, Third Edition, P39-40, screened for transformants with ampicillin resistance.
  • the packaging plasmid pMDLg/pRRE purchased from Addgene, Catalog: 12251
  • the packaging plasmid pRSV-REV purchased from Addgene, Catalog: 12253
  • the outer shell protein particle pMD2G purchased from Addgene, Catalog: 12259 was used to complete the packaging of the virus particles.
  • HEK293 cells purchased from Clontech, Cat. No 632180
  • the cell density of the inoculation day was controlled to be about 80%;
  • Each plasmid component, CaCl 2 solution, TE buffer is thoroughly mixed in a 50 ml centrifuge tube, and the above mixture is slowly added to another centrifuge tube in which the HBS solution has been placed;
  • Figure 3 is a fluorescence micrograph of a HEK293 cell line co-transfected with four plasmids. The result is shown in Figure 3.
  • GFP is a photo under fluorescence
  • Light is a white light photo in the same field of view
  • Merge is a two-field view. Photo.
  • Viral particles were resuspended as virus particle stocks in an appropriate amount of TBS solution (800 mg NaCl, 20 mg KCl, 300 mg Tris base in 100 ml deionized water, pH 8.0), dispensed and stored at -80 °C.
  • TBS solution 800 mg NaCl, 20 mg KCl, 300 mg Tris base in 100 ml deionized water, pH 8.0
  • HEK293 cells were seeded in 96-well plates, seeded at a density of 4,000 cells per well, and placed in a cell culture incubator overnight;
  • n is the gradient dilution factor
  • pCDH-seTRAIL lentivirus titer is 1 ⁇ 10 6 TU/ ⁇ l
  • pCDH (empty vector control) lentivirus titer is 1 ⁇ 10 6 TU / ⁇ l
  • the umbilical cord is cut by the umbilical cord, and the umbilical cord is washed with physiological saline, and then disinfected with medical alcohol.
  • the umbilical cord is placed in the umbilical cord preservation solution at a constant temperature of 2-8 ° C.
  • the obtained umbilical cord was washed with 0.9% sodium chloride injection and repeated 2 to 3 times to remove blood stains. 75% ethanol was immersed in the entire umbilical cord for sterilization. The sodium chloride injection was repeatedly washed to remove residual ethanol.
  • the umbilical cord was cut into a number of about 2 to 5 cm with a sterile surgical scissors to remove congestion and clots in the small blood vessels of the umbilical cord.
  • the white connective tissue between the amniotic membrane and the blood vessel is Huatong's glue, which is torn off with a gingival sputum, placed in a sterile dish, and an appropriate amount of 0.9% sodium chloride injection is added to wash the colloid.
  • the weighed Huatong's colloid was cut into a tissue homogenate block of 1 to 4 mm 3 with a sterile tissue scissors, and 0.9% sodium chloride injection was added thereto, and the mixture was centrifuged at 800 to 900 g for 5 minutes. Collect the last wash solution for sterility. According to the weight of the colloid, add appropriate medium, and the concentration of the homogenized tissue homogenate is about 04-0.7g/ml. After pipetting the tissue homogenate block uniformly, the tissue homogenate block is inoculated into the T75 flask, and the medium is added. Mixed culture.
  • the culture flask is placed in a flat state to distribute the tissue homogenate block as evenly as possible over the entire bottom surface, and the culture flask is placed in a constant temperature and humidity incubator of carbon dioxide. Culture conditions: 37.0 ⁇ 0.5 ° C, carbon dioxide volume fraction was 5.0 ⁇ 0.2%.
  • the first change the tissue was cultured until the 5th to 7th day for the full amount of liquid exchange.
  • the unattached tissue blocks in the culture flask are combined with the old medium and transferred to a centrifuge tube, 800-900 g, centrifuged for 5 min, the supernatant is removed, and the residual tissue pieces after centrifugation are added to the appropriate amount of fresh medium.
  • the liquid tube was blown evenly, and the same amount was divided into the original culture flask, and then the medium was added.
  • the culture flask is placed flat so that the tissue block is evenly distributed throughout the bottom surface, and the CO 2 constant temperature and humidity incubator is placed to continue the culture.
  • the second liquid change the culture was changed for 10 to 13 days. Slightly tilt the flask, pipette a small amount of the old medium, and add an equal amount of fresh medium. The culture was continued by placing a CO 2 incubator.
  • the area percentage of the cell clonal group reaches 70% to 80%, it is digested and harvested.
  • the medium supernatant was removed and the cells were washed with 0.9% sodium chloride injection.
  • Add appropriate amount of digestive enzyme to the culture flask until the bottom of the culture flask is infiltrated. After standing for 1 min, the culture flask was taken and observed under an inverted microscope. The cells were round, and most of the adherent tissue blocks and cells fell off, and the digestion was terminated (digestion time was less than 5 min).
  • the cell suspension was transferred into a centrifuge tube, and a small amount of 0.9% sodium chloride injection was used to rinse the bottle wall.
  • the washing liquid was transferred into a centrifuge tube, and the pipette was suspended and suspended for 30 seconds, filtered through a 100 ⁇ m sterile filter, and the filtrate was centrifuged, 300 g. , 10min. The washing supernatant was discarded and the cells were resuspended in 0.9% sodium chloride injection.
  • GFP is a photo under fluorescence
  • Light is a white light photo in the same field of view
  • Merge is an integrated photo of two fields of view.
  • Example 6 Activity of MSC cells expressing and secreting TRAIL protein in a lentiviral vector infected with a lentiviral vector
  • the collected cell culture supernatant was analyzed for the TRAIL protein content in the supernatant using Abcam's TRAIL Human ELISA Kit (Catalog: ab46074), and the recombinant human TRAIL provided in the kit was accurately operated according to the kit instructions. Make a standard curve.
  • the TRAIL protein concentration in the supernatant of MSC medium infected with lentivirus pCDH-seTRAIL was approximately 634.93 pg/ml.
  • the TRAIL protein concentration in the MSC medium supernatant of the control empty vector lentiviral pCDH was approximately 32.96 pg/ml. This amount is the test error and the instrument reading background error range.
  • Example 7 Inhibition of human glioma cell line U87 cells by MSC cells secreting TRAIL protein
  • the collected cell culture supernatant of the MSC infected with the virus particles was centrifuged at 1,000 rpm for 10 minutes to remove the remaining cells, and the supernatant was aspirated as a conditioned medium;
  • the conditioned medium was serially diluted in a concentration gradient of 2% FBS in ⁇ -MEM medium, and the concentrations of 1, 0.5, 0.25, and 0.125 were set;
  • Human glioma cell line U87 cells (purchased from ATCC, Cat. No. HTB-14) cultured in ⁇ -MEM medium containing 10% FBS, seeded in 96-well plates at a density of 3,000 cells per well, placed in a 96-well plate. Incubate in a cell culture incubator overnight;
  • the absorbance values of the respective wells were measured at a wavelength of 490 nm and a reference wavelength of 690 nm using a Thermo Scientific Mulitiskan microplate reader;
  • tumor inhibition rate (%) (blank hole absorbance value - conditioned medium treatment hole absorbance value) / blank hole absorbance value X100
  • MSC can express and secrete a large amount of biologically active TRAIL protein into the cell culture medium, and has significant growth on U87 cells. Inhibition.
  • Example 8 Stability of TRAIL protein secreted by MSC cells infected with lentiviral vector
  • the supernatant of MSC conditioned medium infected with lentivirus pCDH-seTRAIL obtained in Example 6 was analyzed (the concentration of TRAIL protein in the supernatant was detected as: 634.93 pg/ml);
  • the MSC conditioned medium supernatant of the control empty vector lentiviral pCDH was infected as the first control medium;
  • the fresh medium supernatant was used as the second control medium (the concentration of TRAIL protein in the supernatant was detected to be about 0);
  • the MSC conditioned medium infected with lentivirus pCDH-seTRAIL was supernatantd, the supernatant of the first control medium in which rhTRAIL was dissolved, and the supernatant of the second control medium in which rhTRAIL was dissolved was placed in a 37 ° C warm bath at different times. (0, 3, 6, 12, 24, 48h) A small amount of supernatant was taken and quickly stored in a refrigerator at -70 °C.
  • each sample was determined by the ELISA method as in Example 6. TRAIL protein content.
  • the protein content at 0 h of each treatment group was 100%, and the TRAIL protein residual rate at each time point of each treatment group was calculated according to the following formula:
  • Residual rate (TRAIL concentration at each time point / TRAIL concentration at 0h time point) x100%
  • Example 9 Inhibition of human glioma cells by MSC cells secreting TRAIL protein in an animal model in nude mice
  • the experimental animals were 4-6 weeks old male nude mice (Chinese University of Hong Kong Experimental Animal Center, BALB/C nude mice). Breeding under standard experimental conditions: 12 hours light - 12 hours dark cycle, free access to water and food.
  • MSCs infected with lentivirus pCDH-seTRAIL, MSCs infected with control vector lentivirus pCDH, and human glioma cell line U87 cells were respectively in ⁇ -MEM medium containing 10% FBS, 37 ° C, 5% CO 2 Culture under saturated humidity conditions. After the animals were acclimated to the culture environment for 4 days, U87 cells were injected subcutaneously into nude mice, and each animal was inoculated into two positions, which were the left side of the back of the nude mouse and the right side symmetric thereto, and the inoculation of U87 cells at each locus. The amount was 2 x 10 6 cells and the injection volume was 100 ul. The entire operation is done in a clean bench.
  • mice with uniform tumor size on the left and right sides 8 mice with uniform tumor size on the left and right sides (the diameter of the vernier caliper was about 5 mm) were selected according to the tumor volume of the animals, and 2 ⁇ 106 infection controls were injected into the left tumor block.
  • the MSCs of the vector lentivirus pCDH were injected with 2x106 MSCs infected with lentivirus pCDH-seTRAIL at the right tumor site, and the injection volume was 100 ul.
  • Figure 8 shows the average tumor volume measurement results (volume unit mm 3 ) between the two groups during the experiment.
  • the tumor volume of the two groups began to differentiate.
  • the tumor volume of the MSCs injected with lentivirus pCDH-seTRAIL was gradually lower than that of the control group injected with MSCs infected with the control vector lentiviral pCDH. And on the 12th day and the 16th day showed a significant difference (P ⁇ 0.05).
  • the experimental results demonstrate that the MSC cells of the present invention infected with a lentiviral vector capable of secreting a TRAIL protein insert have a significant therapeutic effect on human glioma in animals.
  • the inventors of the present invention have unexpectedly found that umbilical cord mesenchymal stem cells prepared by the method of the present invention are effective in inhibiting brain tumors, particularly gliomas, in animals.
  • One of the reasons for this unexpected discovery is a secreted TRAIL protein soluble fragment construct constructed based on the present invention and a lentiviral expression vector containing the construct.
  • the amino acid sequence of the soluble fragment coding region of the TRAIL protein of the present invention is added to promote the formation of a trimeric structure, which contributes to the stability and activity of the soluble fragment of the expressed TRAIL protein. Expression of a secreted TRAIL protein soluble fragment molecule in mammalian cells.
  • the secreted TRAIL protein soluble fragment expression vector constructed by the present invention is added to the upstream region of the TRAIL protein soluble fragment coding gene in the downstream region of the promoter, and a highly efficient secretion signal peptide sequence is added, so that the TRAIL protein cloned downstream can be soluble.
  • the TRAIL protein soluble fragment molecule expressed by the fragment encoding gene is secreted into the extracellular medium, which significantly increases the efficiency of protein expression, and the stability of the soluble fragment of the produced TRAIL protein is unexpectedly increased.
  • the coding gene encoding a soluble fragment of the secreted TRAIL protein can be stably integrated into the genome of the host cell, which is not easy Lost, and the risk of insertional tumor formation is greatly reduced, more secure and reliable.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une construction utilisée pour exprimer des fragments solubles de la protéine TRAIL sécrétée, et un vecteur d'expression lentiviral comprenant ladite construction. L'invention concerne également des cellules souches mésenchymateuses comportant ladite construction intégrée dans leur génome et capables d'exprimer et de sécréter lesdits fragments de protéine TRAIL. L'invention concerne également l'utilisation de ladite construction, dudit vecteur ou desdites cellules souches mésenchymateuses pour traiter les tumeurs cérébrales.
PCT/CN2017/078684 2016-03-30 2017-03-30 Cellules souches mésenchymateuses sécrétant la protéine trail et leur utilisation pour traiter les tumeurs cérébrales Ceased WO2017167209A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/089,992 US20200318137A1 (en) 2016-03-30 2017-03-30 Trail-secreting mesenchymal stem cells and use thereof to treat brain tumors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201610194781.1 2016-03-30
CN201610194781 2016-03-30
CN201710184390.6 2017-03-24
CN201710184390.6A CN107287224A (zh) 2016-03-30 2017-03-24 分泌trail的间充质干细胞及其治疗脑瘤的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/365,375 Continuation US11380251B2 (en) 2020-07-30 2021-07-01 LED display screen calibration method and related apparatus

Publications (1)

Publication Number Publication Date
WO2017167209A1 true WO2017167209A1 (fr) 2017-10-05

Family

ID=59963521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/078684 Ceased WO2017167209A1 (fr) 2016-03-30 2017-03-30 Cellules souches mésenchymateuses sécrétant la protéine trail et leur utilisation pour traiter les tumeurs cérébrales

Country Status (1)

Country Link
WO (1) WO2017167209A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047172A1 (fr) * 2004-10-22 2006-05-04 Immunex Corporation Recepteur tweak
WO2011141558A1 (fr) * 2010-05-12 2011-11-17 Universite De Rennes 1 Vecteur recombiné pour produire et faire sécréter des séquences d'acides aminés d'intérêt par des propionibactéries, et applications associées
CN102250254A (zh) * 2010-05-19 2011-11-23 江苏先声药物研究有限公司 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
CN102898526A (zh) * 2011-07-28 2013-01-30 山东先声麦得津生物制药有限公司 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
CN102921020A (zh) * 2012-10-29 2013-02-13 清华大学深圳研究生院 一种联合治疗肿瘤的基因药物及其应用
CN105693864A (zh) * 2015-08-05 2016-06-22 黑龙江八农垦大学 一种三聚体trail蛋白及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047172A1 (fr) * 2004-10-22 2006-05-04 Immunex Corporation Recepteur tweak
WO2011141558A1 (fr) * 2010-05-12 2011-11-17 Universite De Rennes 1 Vecteur recombiné pour produire et faire sécréter des séquences d'acides aminés d'intérêt par des propionibactéries, et applications associées
CN102250254A (zh) * 2010-05-19 2011-11-23 江苏先声药物研究有限公司 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
CN102898526A (zh) * 2011-07-28 2013-01-30 山东先声麦得津生物制药有限公司 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
CN102921020A (zh) * 2012-10-29 2013-02-13 清华大学深圳研究生院 一种联合治疗肿瘤的基因药物及其应用
CN105693864A (zh) * 2015-08-05 2016-06-22 黑龙江八农垦大学 一种三聚体trail蛋白及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DMITRI, R. ET AL.: "A Humanized Leucine Zipper-TRAIL Hybrid Induces Apoptosis of Tumors both In Vitro and In Vivo", PLOS ONE, vol. 10, no. 4, 7 April 2015 (2015-04-07), pages 1 - 13, XP055318699, ISSN: 1932-6203 *
KEIJI, M. ET AL.: "Molecular Cloning of Nucleobindin, a Novel DNA-Binding Protein that Contains both a Signal Peptide and a Leucine Zipper Structure", BIOCHEMICAL & BIOPHYSICAL RESEARCH COMMUNICATION, vol. 187, no. 1, 31 August 1992 (1992-08-31), pages 375 - 380, XP000978707, ISSN: 0006-291X *
LI, PING: "Cloning, Expression, Antitumor Activity and Mechanisms Analysis of ZS-TRAIL", MEDICINE & PUBLIC HEALTH, CHINA DOCTORAL DISSERTATIONS FULL-TEXT DATABASE, 15 November 2008 (2008-11-15), ISSN: 1674-022X *
YUAN, XIANGFEI: "The Research of Gene Therapy to B-Lymphoma Using stTRALL Driven by a Specific CD 20 Promoter Mediated by Adenovirus Vector", MEDICINE & PUBLIC HEALTH, CHINA DOCTORAL DISSERTATIONS FULL-TEXT DATABASE, 15 June 2014 (2014-06-15), ISSN: 1674-022X *
ZHANG, YANJUN ET AL.: "Inhibiting Effect of CD 20 Promoter-Driven Recombinant Adenovirous-Sttrail on Lymphoma Cell Growth", CHINESE JOURNAL OF CANCER BIOTHERAPY, vol. 22, no. 3, 30 June 2015 (2015-06-30), pages 290 - 298 *

Similar Documents

Publication Publication Date Title
CN110128550B (zh) 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用
CN110499297B (zh) 一种新型溶瘤病毒及其制备方法和应用
US6245330B1 (en) Recombinant adenoviruses coding for glial-derived neurotrophic factor (GDNF)
JP6351799B2 (ja) 癌治療用医薬組成物の製造方法及びその方法によって製造された癌治療用医薬組成物
US20220401491A1 (en) Mesenchymal stem cell expressing trail and cd, and use thereof
US20200318137A1 (en) Trail-secreting mesenchymal stem cells and use thereof to treat brain tumors
CN108570455A (zh) 一种重组单纯疱疹病毒及其用途
JP3244696B2 (ja) ヒト筋肉細胞の単離、増殖および分化
WO2011130749A2 (fr) Identification de mutations dans les glycoprotéines d'enveloppe de virus herpès simplex qui permettent ou augmentent le reciblage de vecteur vers de nouveaux récepteurs non-hsv
CN110760480B (zh) 一种抗肿瘤nk细胞及其制备方法
CN114729320B (zh) 用于将细胞重新程序化为能够呈递抗原的树突细胞2型的组合物、方法及其用途
WO2011090297A2 (fr) Cellule souche adulte humaine pouvant exprimer anti-mdm2 et son utilisation
KR20230117726A (ko) 신규한 피기백(PiggyBac) 트랜스포존 시스템 및 이의 용도
CN114592010A (zh) NK-CAR-MbIL-15细胞及其制备方法和应用
JP4610194B2 (ja) 新規キメラｔｎｆリガンド
ES2744479T3 (es) Agentes medicinales novedosos y usos de los mismos
CN105384826A (zh) 表达嵌合抗原受体的脐血有核细胞及其应用
CN106167791B (zh) MSC-TNF α-AB干细胞及其制备方法和应用
CN112980883B (zh) 一种人γ-干扰素病毒载体及其应用
HU227667B1 (en) Novel expression vectors and uses thereof
WO2017167209A1 (fr) Cellules souches mésenchymateuses sécrétant la protéine trail et leur utilisation pour traiter les tumeurs cérébrales
JPH08501210A (ja) 遺伝子産物の持続的放出のための筋芽細胞の利用
JP7227654B2 (ja) 固形癌及び微生物感染を治療するための方法及び組成物
CN111979204B (zh) 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
KR20180079033A (ko) Igf-1 및 il-10을 분비하는 세포, 및 이의 용도

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17773239

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17773239

Country of ref document: EP

Kind code of ref document: A1